3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014
M2 - Thu Dec 04, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/24zmv5/metastatic) has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - MedImmune, LLC - Novartis AG - Onyx Pharmaceuticals, Inc. - Active Biotech AB - Hutchison MediPharma Limited - OncoMed Pharmaceuticals, Inc. - Mirna Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/24zmv5/metastatic
OMED: 19.77 (-0.42), AZN: 71.80 (-1.80), NVS: 93.52 (-0.82)
OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer
GlobeNewswire - Mon Dec 01, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's "PINNACLE" clinical trial of its anti-Notch2/3 cancer stem cell antibody, tarextumab (OMP-59R5), for the treatment of small cell lung cancer (SCLC).
OMED: 19.77 (-0.42)
OncoMed Presents New Clinical and Biomarker Data From Its Tarextumab and Demcizumab Clinical Trials at the EORTC-NCI-AACR Symposium
GlobeNewswire - Fri Nov 21, 7:00AM CST
Biomarker Studies Demonstrate On-Target Effects of Tarextumab Against Notch Pathway and Cancer Stem Cells in Patients With Pancreatic Cancer
OMED: 19.77 (-0.42)
OncoMed Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
GlobeNewswire - Thu Nov 20, 3:30PM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Sunil Patel, Chief Financial Officer, Senior Vice President, Corporate Development and Finance, will speak at the 26th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 pm Eastern Time.
OMED: 19.77 (-0.42)
OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial of Anti-Notch1 (OMP-52M51) in Oral Plenary Session at the 26th EORTC-NCI-AACR Symposium
GlobeNewswire - Wed Nov 19, 6:50AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented data today from the company's ongoing Phase 1a clinical trial of anti-Notch1 (OMP-52M51) in patients with certain advanced solid tumors during an oral plenary session at the 26 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
OMED: 19.77 (-0.42)
5 Things Celgene Corporation's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 6:51AM CST
Source: U.S. Department of Agriculture via Flickr . Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher . For the quarter, Celgene...
OMED: 19.77 (-0.42), AMGN: 164.53 (-1.55), ABBV: 65.27 (-1.76), CELG: 114.49 (-2.25)
Oncomed Pharmaceuticals' (OMED) CEO Paul Hastings on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST
OMED: 19.77 (-0.42)
OncoMed beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:36PM CST
OMED: 19.77 (-0.42)
OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Nov 04, 3:02PM CST
Raises Year-End Cash Balance Guidance to Over $225 Million From $215 Million
OMED: 19.77 (-0.42)
OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S.
GlobeNewswire - Mon Nov 03, 7:37AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, has been granted a new patent (U.S. Patent No. 8,858,941) in the United States for OncoMed's anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and use of the bispecific antibody in the treatment of cancer. The new patent includes both composition-of-matter and method of treatment claims for the antibody. Related patent applications are pending in the United States, Europe, Japan, China and a number of other countries worldwide.
OMED: 19.77 (-0.42)
OncoMed to Present Clinical and Preclinical Data at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting
GlobeNewswire - Thu Oct 30, 7:31AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present clinical data from three anti-cancer stem cell clinical programs at the 26 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting to be held November 18-21, 2014 in Barcelona, Spain.
OMED: 19.77 (-0.42)
OncoMed to Announce Financial Results for the Third Quarter 2014 on Tuesday, November 4, 2014, After Close of U.S.-Based Financial Markets
GlobeNewswire - Wed Oct 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4, 2014, after the close of U.S.-based financial markets. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review the results beginning at 1:30 p.m. Pacific Time (PT)/4:30 p.m. Eastern Time (ET).
OMED: 19.77 (-0.42)
Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 19.77 (-0.42), AGIO: 119.56 (+0.36), CELG: 114.49 (-2.25)
Global Pancreatic Cancer Market 2014-2018: Key Vendors are Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer
M2 - Thu Oct 09, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjxws/global_pancreatic) has announced the addition of the "Global Pancreatic Cancer Market 2014-2018" report to their offering. Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, accounting for 6.8 percent of the total cancer deaths in the US. The analysts forecast the Global Pancreatic Cancer market to grow at a CAGR of 10.70 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pancreatic Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat different types of pancreatic cancer. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - AB Science - AbGenomics International - Aduro Biotech - Aphios - Celgene - Celsion - Eli Lilly - F. Hoffmann-La Roche - Gilead Sciences - Halozyme Therapeutics - Merrimack Pharmaceuticals - Momenta Pharmaceuticals - Novartis - OncoMed Pharmaceuticals - OncozymePharma - Ostuka Holdings - Pfizer - Rexahn Pharmaceuticas - Zeria Pharmaceutica For more information visit http://www.researchandmarkets.com/research/cm...pancreatic
MACK: 10.64 (+0.42), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), LLY: 69.55 (-2.06), MNTA: 12.16 (-0.04), NVS: 93.52 (-0.82), CELGZ: 3.51 (-0.03)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.74 (-0.01), IMMU: 4.58 (-0.09), ONCY: 0.61 (+0.03), OMED: 19.77 (-0.42), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), MNTA: 12.16 (-0.04), MACK: 10.64 (+0.42), SNTA: 2.87 (+0.04), INSY: 41.00 (+1.82), HALO: 7.99 (-0.16), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76), NVS: 93.52 (-0.82), CELGZ: 3.51 (-0.03)
OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Oct 07, 7:39AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed, will speak today at the 13 Annual BIO Investor Forum being held in San Francisco, CA. To access the live webcast and subsequent archived recording for the presentation, please visit the Investors tab on the OncoMed website at www.oncomed.com.
OMED: 19.77 (-0.42)
OncoMed Pharmaceuticals Announces Selection of First Small Molecule Product Candidate Targeting the Wnt Pathway Under Collaboration With Bayer Pharma AG
GlobeNewswire - Tue Sep 30, 7:31AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the advancement of the first small molecule Wnt pathway inhibitor under its collaboration with Bayer Pharma AG. The small molecule product candidate is advancing to preclinical development triggering a $2 million milestone payment to OncoMed.
OMED: 19.77 (-0.42)
OncoMed Presents Encouraging Data From Clinical Trials of Tarextumab (Anti-Notch2/3) in Pancreatic Cancer and Small Cell Lung Cancer at the ESMO 2014 Congress
GlobeNewswire - Mon Sep 29, 6:00AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented promising data on safety and anti-tumor activity from the ALPINE and PINNACLE Phase 1b clinical studies of tarextumab (anti-Notch2/3, OMP-59R5) at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain.
OMED: 19.77 (-0.42)
OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO
GlobeNewswire - Sun Sep 28, 6:00AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented safety and efficacy data from two Phase 1b clinical trials of demcizumab (anti-DLL4, OMP-21M18) in pancreatic cancer and non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain.
OMED: 19.77 (-0.42)